Abstract 1297
Background
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. However, not all patients with mismatch repair deficiency respond to the PD-1 blockade treatment. To understand the different responses, we evaluated tumor micro-environment such as PD-L1 expression in relationship with tumor infiltrating immune cells.
Methods
FL multiplex IHC for PD-L1, CD8, CD3, CD68, and pan-cytokeratin (panCK) on BenchMark ULTRA instrument stained 54 pre-pembrolizumab treatment patient resection and biopsy specimens including pancreatic, colorectal and cholangiocarcinoma. 17 are mismatch-repair proficient (13 PD, 3 SD, and 1 CR) and 37 deficient (5 PD, 10 SD, 9 CR, and 13 PR). Whole slide images by Zeiss AXIO Z1 were analyzed with in-house dPath automated algorithm. PD-L1+/- T-cells (CD3+), cytotoxic T-cells (CD3+ and CD8+), T helper cells (CD3+ and CD8-), macrophages (CD68+), and tumor cells (panCK+) were identified. Fractions of PD-L1+ phenotypes, area density and spatial relationships of phenotypes in pathologist-annotated tumor/peritumor regions, the panCK+ epithelial tumor and panCK- stroma were computed.
Results
Random forest modelling, logistic regression and Relieff feature selection followed by quadrant discriminant analysis were used to assess the relationship of multiplex IHC readouts to anti-PD-1 treatment responses. Different groupings were used, e.g. PR + CR vs. SD + PD, and PR + CR + SD vs. PD, etc. Fraction of PD-L1+ macrophages and fraction of PD-L1+ T helper cells in tumor region, stroma, and epithelial tumor were identified most important features. Mpx IHC achieves 89% accuracy over 70% with mismatch repair status alone.
Conclusions
Multiplex IHC together with automated image analysis provides a tool to evaluate multiple biomarkers and their special relationships in the tumor micro-environment. In a cohort of 54 patient specimens, exploratory analysis of multiplex IHC data suggests that the knowledge of PD-L1 expression on various immune cell phenotypes aids in better predicting response to anti-PD-1 therapy compared to mismatch repair status alone.
Clinical trial identification
Legal entity responsible for the study
Roche Diagnostics/Ventana Medical Systems, Inc.
Funding
Roche Diagnostics/Ventana Medical Systems, Inc.
Editorial Acknowledgement
Disclosure
W. Zhang, M. Khojasteh, A. Hubbard, X. Wang, J.L. Munoz-Rodriguez, D. Jiang, Z. Cai, J. Li, L. Pestic-Dragovich, L. Tang: Employee: Roche Diagnostics. J. Martin, S. Kamthamraju: Contractor employee: Roche Diagnostics. R. Anders: Financial relationships: Merck, BMS, 5 Prime Therapeutics, FLX Bio, Adaptive Biotech. L. Diaz: Founder: Personal Genome Diagnostics, PapGene, PagerBox.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract